All > Iowa > Pad

SELUTION SLR™ 018 DEB for Peripheral Arterial Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Peripheral Arterial Disease+1 MoreSELUTION SLR™ 018 DEB - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study aims to demonstrate the safety and efficacy of the SELUTION SLR™ 018 DEB compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).

Eligible Conditions
  • Peripheral Arterial Disease
  • Superficial Femoral Artery Stenosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Misago® RX Self-expanding Peripheral Stent
1
Latiglutenase
1
Perivascular dexamethasone

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 12 months

12 months
Freedom from target limb above-ankle amputation and clinically-driven target lesion revascularization (CD-TLR) at 12 months.
Interventional procedure
30 days
Freedom from death (device and procedure related) through 30 days post-index procedure

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Misago® RX Self-expanding Peripheral Stent
2
Latiglutenase
2
Perivascular dexamethasone

Trial Design

2 Treatment Groups

Plain (Uncoated) Balloon Angioplasty (PTA)
1 of 2
SELUTION SLR™ 018 DEB
1 of 2

Active Control

Experimental Treatment

300 Total Participants · 2 Treatment Groups

Primary Treatment: SELUTION SLR™ 018 DEB · No Placebo Group · N/A

SELUTION SLR™ 018 DEB
Device
Experimental Group · 1 Intervention: SELUTION SLR™ 018 DEB · Intervention Types: Device
Plain (Uncoated) Balloon Angioplasty (PTA)
Device
ActiveComparator Group · 1 Intervention: Plain (Uncoated) Balloon Angioplasty (PTA) · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months

Who is running the clinical trial?

NAMSAOTHER
30 Previous Clinical Trials
13,207 Total Patients Enrolled
1 Trials studying Peripheral Arterial Disease
159 Patients Enrolled for Peripheral Arterial Disease
M.A. Med Alliance S.A.Lead Sponsor
7 Previous Clinical Trials
5,031 Total Patients Enrolled
4 Trials studying Peripheral Arterial Disease
1,203 Patients Enrolled for Peripheral Arterial Disease

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Subjects must be female and of childbearing potential.
You have a target lesion within the superficial femoral artery and/or proximal popliteal artery.
You have a total occlusion with lesion length between 3 and 10 centimeters.
Documented ischemia with Rutherford classification category 2, 3 or 4.
You have at least one target lesion in the SFA or PPA.
You are willing and able to provide informed consent and comply with study procedures and required follow-up evaluations.
You have a lesion of 70-99% stenosis with lesion length between 3 and 20 cm.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top